362 related articles for article (PubMed ID: 27422962)
21. NF-kappa B as a target for cancer therapy.
Melisi D; Chiao PJ
Expert Opin Ther Targets; 2007 Feb; 11(2):133-44. PubMed ID: 17227230
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of NF-kappaB signaling: 785 and counting.
Gilmore TD; Herscovitch M
Oncogene; 2006 Oct; 25(51):6887-99. PubMed ID: 17072334
[TBL] [Abstract][Full Text] [Related]
23. The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity.
Mauro C; Zazzeroni F; Papa S; Bubici C; Franzoso G
Methods Mol Biol; 2009; 512():169-207. PubMed ID: 19347278
[TBL] [Abstract][Full Text] [Related]
24. Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer.
Baldwin AS
Immunol Rev; 2012 Mar; 246(1):327-45. PubMed ID: 22435564
[TBL] [Abstract][Full Text] [Related]
25. Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership.
Dobrovolskaia MA; Kozlov SV
Curr Cancer Drug Targets; 2005 Aug; 5(5):325-44. PubMed ID: 16101381
[TBL] [Abstract][Full Text] [Related]
26. NF-kappaB and IKK as therapeutic targets in cancer.
Kim HJ; Hawke N; Baldwin AS
Cell Death Differ; 2006 May; 13(5):738-47. PubMed ID: 16485028
[TBL] [Abstract][Full Text] [Related]
27. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Aggarwal BB; Shishodia S; Takada Y; Banerjee S; Newman RA; Bueso-Ramos CE; Price JE
Clin Cancer Res; 2005 Oct; 11(20):7490-8. PubMed ID: 16243823
[TBL] [Abstract][Full Text] [Related]
28. Nuclear Factor Kappa B: A Potential Target to Persecute Head and Neck Cancer.
Monisha J; Roy NK; Bordoloi D; Kumar A; Golla R; Kotoky J; Padmavathi G; Kunnumakkara AB
Curr Drug Targets; 2017; 18(2):232-253. PubMed ID: 26844566
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
30. SRS06, a new semisynthetic andrographolide derivative with improved anticancer potency and selectivity, inhibits nuclear factor-κB nuclear binding in the A549 non-small cell lung cancer cell line.
Lim JC; Jeyaraj EJ; Sagineedu SR; Wong WS; Stanslas J
Pharmacology; 2015; 95(1-2):70-7. PubMed ID: 25613753
[TBL] [Abstract][Full Text] [Related]
31. Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells.
Pollock JK; Greene LM; Nathwani SM; Kinsella P; O'Boyle NM; Meegan MJ; Zisterer DM
Invest New Drugs; 2018 Aug; 36(4):523-535. PubMed ID: 29460212
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers.
Li Y; Zhao B; Peng J; Tang H; Wang S; Peng S; Ye F; Wang J; Ouyang K; Li J; Cai M; Chen Y
Drug Resist Updat; 2024 Mar; 73():101042. PubMed ID: 38219532
[TBL] [Abstract][Full Text] [Related]
33. Modulating multidrug resistance to drug-based antitumor therapies through NF-κB signaling pathway: mechanisms and perspectives.
Wu D; Tian S; Zhu W
Expert Opin Ther Targets; 2023; 27(6):503-515. PubMed ID: 37314372
[TBL] [Abstract][Full Text] [Related]
34. Engineered nanoparticles as emerging gene/drug delivery systems targeting the nuclear factor-κB protein and related signaling pathways in cancer.
Eskandani R; Kazempour M; Farahzadi R; Sanaat Z; Eskandani M; Adibkia K; Vandghanooni S; Mokhtarzadeh A
Biomed Pharmacother; 2022 Dec; 156():113932. PubMed ID: 36411621
[TBL] [Abstract][Full Text] [Related]
35. E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets.
Huang Y; Chen R; Zhou J
Curr Cancer Drug Targets; 2016; 16(9):765-772. PubMed ID: 26881929
[TBL] [Abstract][Full Text] [Related]
36. NF-kappaB regulation in the immune system.
Li Q; Verma IM
Nat Rev Immunol; 2002 Oct; 2(10):725-34. PubMed ID: 12360211
[TBL] [Abstract][Full Text] [Related]
37. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.
Baud V; Karin M
Nat Rev Drug Discov; 2009 Jan; 8(1):33-40. PubMed ID: 19116625
[TBL] [Abstract][Full Text] [Related]
38. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R
Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-Activation.
Kanzaki H; Mukhopadhya NK; Cui X; Ramanujan VK; Murali R
Monoclon Antib Immunodiagn Immunother; 2016 Feb; 35(1):1-11. PubMed ID: 26871511
[TBL] [Abstract][Full Text] [Related]
40. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K
Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
